Related Experiment Video

Updated: Jul 4, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Identification of potential chemoresistance genes in osteosarcoma

Denise Katherine Walters1, Patrick Steinmann, Bettina Langsam

  • 1Laboratory for Orthopaedic Research, Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.

Anticancer Research
|May 30, 2008
PubMed
Abstract

Insights

Osteosarcoma (OS) chemoresistance in metastatic patients is poorly understood. This study identified genes like ABCG2 and ADD3 that may contribute to OS chemoresistance, offering targets for improved treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma (OS) is an aggressive bone cancer with poor survival rates for metastatic patients.
  • Chemoresistance significantly limits treatment efficacy in osteosarcoma.
  • Mechanisms driving osteosarcoma chemoresistance are largely unknown.

Purpose of the Study:

  • To investigate the genetic basis of chemoresistance in osteosarcoma.
  • To identify genes associated with increased metastatic potential and drug resistance in OS cell lines.

Main Methods:

  • Examined the effects of cisplatin, doxorubicin, and etoposide on OS cell lines.
  • Utilized Affymetrix Genechip analysis for differential gene expression profiling.
  • Employed a MG-63 cell line and sub-line model to correlate metastatic potential with chemoresistance.

Main Results:

  • A correlation was observed between increased metastatic potential and heightened chemoresistance in OS cells.
  • Microarray analysis revealed differential expression of genes including ABCG2, ADD3, NMT2, WNTSa, and PTN.
  • These identified genes are potentially involved in the mechanisms of chemoresistance.

Conclusions:

  • Identifying genes contributing to chemoresistance is crucial for understanding patient responsiveness.
  • Further characterization of these genes' roles is essential for overcoming chemoresistance in osteosarcoma.
  • This research provides potential therapeutic targets for improving osteosarcoma treatment outcomes.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues02:35

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on: March 22, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...